-$0.53 Earnings Per Share Expected for Aravive, Inc. (NASDAQ:ARAV) This Quarter

Equities research analysts expect Aravive, Inc. (NASDAQ:ARAVGet Rating) to post ($0.53) earnings per share (EPS) for the current quarter, Zacks Investment Research reports. Two analysts have made estimates for Aravive’s earnings, with estimates ranging from ($0.56) to ($0.50). Aravive reported earnings per share of ($0.44) in the same quarter last year, which would indicate a negative year-over-year growth rate of 20.5%. The firm is expected to report its next quarterly earnings results on Monday, January 1st.

On average, analysts expect that Aravive will report full year earnings of ($2.08) per share for the current year, with EPS estimates ranging from ($2.34) to ($1.70). For the next financial year, analysts anticipate that the company will post earnings of ($2.43) per share, with EPS estimates ranging from ($2.67) to ($2.11). Zacks Investment Research’s EPS calculations are an average based on a survey of sell-side research analysts that follow Aravive.

Aravive (NASDAQ:ARAVGet Rating) last announced its quarterly earnings data on Thursday, March 31st. The company reported ($0.62) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.64) by $0.02. Aravive had a negative return on equity of 68.29% and a negative net margin of 526.08%. The company had revenue of $0.99 million for the quarter, compared to the consensus estimate of $1.56 million.

Several equities analysts have recently issued reports on ARAV shares. Piper Sandler reduced their target price on Aravive from $14.00 to $9.00 in a report on Friday, April 1st. Zacks Investment Research lowered Aravive from a “hold” rating to a “sell” rating in a report on Monday, April 4th.

Hedge funds have recently modified their holdings of the stock. Massmutual Trust Co. FSB ADV purchased a new stake in shares of Aravive in the third quarter worth $35,000. Geneos Wealth Management Inc. raised its position in shares of Aravive by 128.3% in the third quarter. Geneos Wealth Management Inc. now owns 12,810 shares of the company’s stock worth $47,000 after buying an additional 7,200 shares in the last quarter. Franklin Resources Inc. purchased a new stake in Aravive during the third quarter valued at about $141,000. Millennium Management LLC raised its position in Aravive by 142.8% during the second quarter. Millennium Management LLC now owns 92,046 shares of the company’s stock valued at $550,000 after purchasing an additional 54,138 shares in the last quarter. Finally, Acadian Asset Management LLC raised its position in Aravive by 100.8% during the fourth quarter. Acadian Asset Management LLC now owns 109,169 shares of the company’s stock valued at $238,000 after purchasing an additional 54,793 shares in the last quarter. Institutional investors own 42.83% of the company’s stock.

Shares of Aravive stock traded down $0.11 on Tuesday, hitting $1.47. The company had a trading volume of 90,227 shares, compared to its average volume of 64,621. The stock has a market capitalization of $31.01 million, a price-to-earnings ratio of -0.76 and a beta of 2.57. Aravive has a 1 year low of $1.41 and a 1 year high of $6.94. The stock has a 50 day moving average of $1.92 and a 200-day moving average of $2.58.

Aravive Company Profile (Get Rating)

Aravive, Inc, a clinical-stage biopharmaceutical company, develops treatments for life-threatening diseases, including cancer and fibrosis in the United States. Its lead product candidate is batiraxcept, an ultrahigh-affinity, decoy protein that targets the GAS6-AXL signaling pathway, which is in Phase III clinical trial for the treatment of platinum- resistant recurrent ovarian cancer; and in Phase Ib/II clinical trial for the treatment of clear cell renal cell carcinoma and pancreatic adenocarcinoma.

Read More

Get a free copy of the Zacks research report on Aravive (ARAV)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Aravive (NASDAQ:ARAV)

Receive News & Ratings for Aravive Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aravive and related companies with MarketBeat.com's FREE daily email newsletter.